Glaukos Q3 revenue $133.5M (+38% YoY); raises 2025 guide, introduces 2026 outlook

GLAUKOS Corp

2025-Q3 EPS reported -$0.95 revenue$364,321,000

Record net sales $133.5M, up 38% YoY; U.S. Glaucoma sales $80.8M (+57% YoY).
GAAP net loss $16.2M (($0.28)/share) improved from $21.4M loss prior year; non-GAAP loss $9.2M (($0.16)/share).
Raised FY2025 net sales guidance to $490-495M (from $480-486M); introduced preliminary FY2026 guidance $600-620M.
Gross margin ~78% (non-GAAP ~84%); ended quarter with $277.5M cash, no debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.